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Sleep Disordered Breathing and Heart Failure and the Role of Pacing
and Cardiac Resynchronization Therapy
RAYMOND KIN-MAN MIU, HUNG-FAT TSE, CHU-PAK LAU
From Division of Cardiology, Department of Medicine, Queen Mary Hospital, Hong Kong SAR
MIU ET AL.: Sleep Disordered Breathing and Heart Failure and the Role of Pacing and Cardiac Resynchronization
Therapy. At least 20% of hospital admissions among persons older than 65 are due to heart failure (HF).1 In 1993,
there were 875,000 hospitalizations in the United States with the first listed discharge diagnosis as HF, and about
2.5 million had it listed as an associated condition.2 Approximately 60 percent of health care expenditures for HF
were for hospital care. There were three million office visits annually for HF at a cost of 3 billion dollars per year.
Despite the advances of pharmacological therapies, revascularization procedures, device therapies and meticulous
cardiac surgical techniques in the last decade, the short and long term mortality of this condition remains high. In
the population based sample from the Framingham Heart Study, the one year mortality among men and women was
28 percent and 24 percent and five year mortality was 59 percent in men and 45 percent in women respectively.3
Unfortunately, much of our understanding and management of heart failure have been focused on while the patient
is awake. Relatively little attention is paid to the pathophysiological sequelae of heart failure that occur nocturnally.
"Nocturnal" management of heart failure may have an important impact. The purpose of this article is to review the
pathogenesis and management of heart failure through management of sleep related breathing disorder. (J HK Coll
Cardiol 2006;14:6-15)
Central sleep apnoea, heart failure, obstructive sleep apnoea
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Clinical Features and Diagnosis of
Sleep Disordered Breathing
Though sleep disordered breathing (SDB) has
been described for almost two hundred years ago, it
was not until 1965 when Gastaut and co-workers
provided a more comprehensive and scientific
description of this disease entity.4 They simultaneously
recorded sleep electrophysiologically and breathing in
a patient with the "Pickwickian syndrome" and
characterized different types of apnoea. They also
postulated that the sleepiness was due to the repetitive
arousals associated with the resumption of breathing
that terminated apnoeic events.
Two forms of sleep disordered breathing (SDB)
are now recognized: obstructive sleep apnoea (OSA)
and central sleep apnoea (CSA). In the former, episodes
of apnoea or hypopnoea occur during sleep as a result
of airway obstruction at the level of the pharynx. During
the period of airflow obstruction, the inspiratory effort
of breathing increases substantially which leads to
dysynchrony of thoracoabdominal movement. OSA is
usually associated with symptoms like loud snoring,
restless sleep, nocturnal dyspnoea, headaches in the
morning, and excessive daytime sleepiness. On the
contrary, the breathing disorder of CSA is characterized
by complete or partial withdrawal of central respiratory
drive to the muscles of respiration during sleep.
Thoracoabdominal respiratory movement however
remains in phase.
Polysomnography is the "gold standard"
diagnostic tool for assessing SDB. Measurement of
several sleep parameters allows diagnosis of the type
of SDB and its severity. The apnoea-hypopnoea index
(AHI) − the number of obstructive events per hour −
is the most commonly used measurement to quantify
OSA: mild OSA - 5 to 15 events/h; moderate - 15 to
30 events/h; and severe - 30 events/h.5 A "negative"
polysomnographic study does not exclude mild OSA,
however, because there is night-to-night variability in
the occurrence of obstructive events.
There is no consensus on the cut-off AHI value
in the diagnosis of sleep apnoea in the scientific
community. From most of the medical literature, the
diagnosis of sleep apnoea is generally based on the
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demonstration of an AHI of 10-15/hr.6,7 If the apnoeic
episode occurs together with one or more symptoms of
snoring, restless sleep, morning headaches, and
excessive daytime sleepiness, it constitutes a sleep
apnoea syndrome (SAS). To differentiate whether the
apnoeic or hypopnoeic events are obstructive or central
in nature, current standards for PSG require the
simultaneous monitoring of sleep structure, cardiac
rhythm, oxyhaemoglobin saturation, and respiration
using noninvasive means such as respiratory inductance
plethysmography.5

Epidemiology of Sleep Disordered
Breathing in the Normal Population
OSA is the most common form of SDB, affecting
thousands of patients each year alone in the U.S.1 Initial
descriptions of OSA were of severe apnoea in obese,
middle-age male patients.8,9 It now becomes apparent
that clinicians are recognizing OSA in their patients with
increasing frequency. In the US, there was a 12-fold
increase in the annual number of patients diagnosed with
sleep apnoea between 1990 and 1998, from 108,000 to
over 1.3 million.10
All studies have shown that OSA is a common
disorder that represents a huge public health problem.11
A large prevalence study in state employees found that
undiagnosed sleep disordered breathing "is prevalent
and has a wide range of severity in middle aged women
and men".12 In this study, 9.1 percent of men and 4.0
percent of women had apnoea/hypopnea indices of 15
or more events per hour.
The reported prevalence of OSA is variable
depending on the methodology used. However, three
large-scale studies using polysomnography have
reported similar prevalence estimates for OSA.13-15 The
Wisconsin Sleep Cohort Study showed that 25% of
middle age men and 10% of middle-age women had
SDB (AHI 5/hr), with 4% of men and 2% of women
also having hypersomnolence, fulfilling the current
diagnostic criteria for the sleep apnoea syndrome. In
Hong Kong, a community-based study of sleep apnoea
among 784 middle-aged (age 30-60) men in Hong Kong
using full PSG estimated the prevalence of OSA
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syndrome (AHI >5/hr and excessive daytime sleepiness)
to be 4.1%. 16 On the other hand, using the similar
methodology and diagnostic criteria, the same group of
researchers showed a lower prevalence of OSA
syndrome (2.2%) among the female cohort.17 In both
men and women, body mass index (BMI) and age are
two independent risk factors of SDB among both gender.

rises.23 On the contrary, episodic surges in sympathetic
discharge, heart rate, and blood pressure occur in rapid
eye movement (REM) sleep. However, since an average
human being spends about 85% of sleep in NREM stage,
the average blood pressure and heart rate during sleep
remain below waking levels.21

Pathophysiology and Impact of OSA in Heart
Failure

Epidemiology of Sleep Disordered
Breathing in Patients with Heart Failure

OSA exerts its effect in the progression and
perpetuation of heart failure in four major aspects:
Mechanical, haemodynamic, humoral and vascular
endothelial effects.

Obstructive Sleep Apnoea (OSA)
In the Sleep Heart Health Study, comprising 6424
men and women, the presence of OSA (defined as AHI
>=11/hr) conferred a 2.38 relative increase in the
likelihood of having HF, independent of other known
risk factors.18 In the 2 largest case series of patients with
HF undergoing polysomnography, OSA was diagnosed
in 37% of 45019 and 11% of 8120 subjects studied. The
prevalence of OSA was greater in men (38%) than in
women (31%).19 Risk factors for OSA differ between
men and women; the main risk factor in men is obesity,
whereas in women it is older age.

Central Sleep Apnoea (CSA)
Data regarding the prevalence of CSA in heart
failure is sparse. In the largest studies involving 450
and 81 patients respectively, the reported prevalences
of CSA were 33% and 40%. 19,20 The principal risk
factors for CSA are male sex, hypocapnia, atrial
fibrillation, and increasing age, but not obesity. For
reasons that remain to be elucidated, CSA is rarely seen
in women with HF.

Effect of Sleep on
Cardiovascular Physiology
The stage of non-rapid eye movement (NREM)
sleep, which constitutes approximately 85% of total
sleep time is a quiescent period for the cardiovascular
system. Metabolic rate, sympathetic nervous system
activity, heart rate, cardiac output, and peripheral
vascular resistance decrease,21,22 whereas the vagal tone
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Mechanical
During sleep, there is reduced tonic input to upper
airway muscles, diminished reflexes that protect the
pharynx from collapse and reduced load compensation.
In subjects with normal pharyngeal anatomy, the partial
withdrawal of pharyngeal dilator muscle tone that
accompanies the onset of sleep is insufficient to cause
pharyngeal collapse. The preponderance of evidence
indicates that the pharynx is abnormal in size and/or
collapsibility in patients with OSA. This together with
the potential mechanism of increase in soft tissue
oedema during supine position in patients with heart
failure puts their airway at high risk of occlusion at the
onset of sleep.24
Hemodynamic
As a result of the mechanical airway obstruction,
the ineffective inspiratory effort to open up the collapsed
airway dramatically reduces the intrathoracic pressure.
This causes an increase in left ventricular transmural
pressure which leads to an increase in afterload25 as well
as impairing the relaxation of the ventricle.26 Moreover,
the augmented venous return to the right ventricular
tends to exert its pressure effect to the left ventricle via
the interventricular septum, potentially jeopardizing left
ventricular filling and stroke volume.27
Neurohumoral
Activation of the sympathetic nervous system,
by both hypoxia and arousal, may induce tachycardia
and peripheral vasoconstriction, further increasing
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ventricular afterload. During apnoea, the reflex arising
from pulmonary stretch receptors that suppresses central
sympathetic discharge during normal breathing ceases,
disinhibiting central sympathetic outflow. The ensuing
hypoxia and hypercapnia further enhance sympathetic
activity by stimulating peripheral and central
chemoreceptors.28,29 The resulting vasoconstriction
raises peripheral resistance, whereas increased cardiac
sympathetic stimulation causes tachycardia and reduces
heart rate variability.30 Even though sleep arousal at the
end of obstructive apnoea encourages the resumption of
airflow by increasing pharyngeal dilator muscle tone,27,31
the ensuing excitatory input from cortical centers will
cause a further release of sympathetic discharge together
with a loss of vagal tone.21,32 In severe OSA, these cycles
of apnoea and arousal can repeat several hundred times
each night, exposing the heart and circulation to great
fluctuations in central sympathetic activity, blood
pressure, and heart rate. Worse yet, the adverse effects
of obstructive apnoea on the cardiovascular system can
be carried over to daytime. As shown by two
investigators, daytime sympathetic nervous activity and
systemic blood pressure are increased in patients with
OSA.32,33 Though the mechanism for this is not entirely
clear, the episodic apnoea-related hypoxia may be
contributory, as hypoxia causes sympathetic activation
and blood pressure elevations that persists after removal
of the hypoxic stimulus.33-35
Vascular Endothelium
Suppression of nitrous oxide (NO) in subjects
with OSA was first demonstrated by Ip et al.36 Moreover,
they also showed that the phenomenon can be reversed
with the use of nocturnal continuous positive airway
pressure (CPAP). Their findings offer support for NO
being one of the mediators involved in the acute
hemodynamic regulation and long-term vascular
remodeling in OSA. Reactive hyperemic blood flow and
vascular conductance after forearm arterial occlusion
were attenuated in patients with OSA compared with
control subjects. 37 After treatment of OSA by CPAP,
reactive hyperemic blood flow and vascular conductance
increased in association with a reduction in sympathetic
nervous system activity. Compromised endothelially
mediated vasodilatation in the setting of increased
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sympathetic vasoconstrictor discharge would
predispose patients with OSA to the development of
hypertension.38
Progression into Heart Failure − The Final Common
Pathway
In summary, the aforementioned potential
mechanisms in OSA probably interact with one another
in the pathophysiology of heart failure, putting extra
burden on the already failing heart. OSA increases left
ventricular (LV) transmural pressure (i.e., afterload)
through the generation of negative intrathoracic pressure
and elevations in systemic blood pressure secondary to
hypoxia, arousals from sleep, and increased sympathetic
nervous system activity (SNA). 39 Apnoea also
suppresses the sympathetic inhibitory effects of lung
stretch receptors, further enhancing SNA. The
combination of increased LV afterload and tachycardia
secondary to increased SNA increases myocardial
oxygen demand in the face of a reduced myocardial
oxygen supply. These conditions predispose a patient
acutely to cardiac ischaemia and arrhythmias, and
chronically could contribute to LV hypertrophy and,
ultimately, failure. The resultant fall in stroke volume
will further increase SNA.

Pathophysiology and Impact of CSA in Heart
Failure
Cheyne-Stokes respiration (CSR) with central
sleep apnoea (CSA) [CSR-CSA] is a breathing disorder
seen in patients with advanced congestive heart failure.
It is characterized by the presence of central apnoeas
and hypopnoeas, alternating with periods of crescendodecrescendo pattern of ventilation with each swing of
ventilation terminating in apnoea. 40,41 Although
controversial, most authorities believe CSA-CSR is a
consequence of HF as it can be partially reversible after
optimal treatment of heart failure.42 Whether CSA is
simply a reflection of a failing heart with elevated left
ventricular filling pressures, or whether, for the same
degree of cardiac dysfunction, CSA exerts unique and
independent pathological effects on the diseased
myocardium is debatable.39,43
While many mechanisms may be contributory to
the pathogenesis of CSA-CSR in heart failure, three
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parameters have been shown to correlate with the
presence of CSA-CSR and associated central sleep
apnoea (CSR-CSA): hyperventilation/hypocapnoea,
upper airway irritability and proongation of the
circulation time.
Hyperventilation
Hyperventilation with hypocapnia (respiratory
alkalosis) is a characteristic feature of some patients
with moderate to advanced HF. It is thought to result
from pulmonary congestion and the subsequent irritation
of pulmonary vagal stretch receptors leading to
hyperventilation. Central apnoea is usually initiated
during sleep by a further acute increase in ventilation
and reduction in PaCO 2 that is triggered by a
spontaneous arousal.44 When arterial CO2 (PaCO2) falls
below the threshold level required to stimulate
breathing, the central drive to respiratory muscles and
airflow cease, and central apnoea ensues.44-46 Several
groups tested the hypothesis that hypocapnia was an
important determinant of CSR-CSA in patients with HF.
Two observations are consistent with this hypothesis.
In two studies, patients with HF and CSR-CSA were
compared to those without CSR-CSA.44,45 There were
no differences in ejection fraction, PaO2, mean nocturnal
oxygen saturation (SaO2), or lung to ear circulation time
between the groups. In addition, neither group had
significant awake nor sleep-related hypoxemia.
However, PaCO2 (33 versus 38 mmHg) and mean sleep
transcutaneous PCO2 (33 versus 43 mmHg) were below
normal and were significantly lower in the patients with
CSR-CSA. Raising the nocturnal PCO 2 markedly
attenuated or abolished the clinical expression of CSRCSA. In one report, for example, constant inhalation of
three percent CO 2 in six patients with severe HF
increased the PaCO 2 by four to five mmHg and
virtually eradicated CSA-CSR duration as a
percentage of total sleep time was reduced from 62
percent to 2.2 percent). 47 A similar benefit can be
achieved by raising the nocturnal PCO 2 with
continuous positive airway pressure 48 or the
administration of oxygen.49
Upper Airway Irritability
As discussed previously in the section of the
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pathophysiology of OSA towards HF, OSA could be
present in up to 37% of HF subjects.19 The presence of
OSA in the setting of CSA-CSR can exert additional
adverse hemodynamic burden to a patient with a failing
heart, further compromising cardiac output and
enhancing the occurrence of arrhythmic events.
Prolongation of Circulation Time
Patients with CSR-CSA do not respond normally
to changes in PaO2. This is probably due to prolongation
of the circulatory time which is characteristic of HF
and which correlates strongly to the length of the CSACSR cycle; the period of time of hyperventilation and
apnoea increases as the circulation time increases.44,50
And that probably reflects delayed transmission of
changes in arterial blood gas tensions from the lungs to
the chemoreceptor which leads to a marked increase in
the oscillation around the set point. Hence, the prolonged
circulation time in HF is contributory to the development
of the Cheyne-Stokes respiratory pattern.
Clinical Importance CSA-CSR and its Potential Role in
the Progression of HF
CSR-CSA is important clinically because its
presence in HF patients has been associated, in a severitydependent manner, with elevations of sympathetic
nervous activity which is an important predictor of HF
progression, arrhythmias, and mortality. 51-53 Most
importantly, CSR-CSA was shown to be an independent
prognostic marker in heart failure.40 Using AHI as an
indicator of the underlying severity of CSR-CSA,
Lanfranchi et al showed that patients with AHI >= 30/
hr had high cardiac mortality at 30 months. In the same
study, the left atrial (LA) area was another independent
prognostic marker of adverse cardiovascular outcome.40
Those patients with the highest risk is identified by a
combination of AHI >30/hr and LA >25 cm2. Successful
treatment of CSR by CPAP leads to a significant
reduction in sympathetic nervous activity51 and may
reduce mortality rates by up to 40% in patients with
CHF and CSR-CSA.54 Since CPAP has beneficial effects
on cardiac function (independent of its effect on CSR),
it remains unclear whether CSR-CSA is a result of a
failing heart or a major contributor of poor outcomes of
patients with HF.

April 2006

J HK Coll Cardiol, Vol 14

MIU ET AL.

Impact of a Hyperadrenergic State in CSA-CSR in HF
Unlike OSA, no negative intrathoracic pressure
is generated during central apnoeas.43,44 Intuitively, the
effect on afterload is less than in OSA. Hence research
focus has been directed towards the hyperadrenergic
effects of CSA as the mechanism for disease
progression. Compared with HF patients matched for
ejection fraction and other clinical characteristics but
without sleep-related breathing disorders, those with
CSA have higher urinary and circulating norepinephrine
concentrations during both sleep and wakefulness.51 The
magnitude of these increases is proportional to the
frequency of arousals from sleep and the degree of
apnoea related hypoxia. Most importantly, the degree
of sympathetic activity can be modified upon initiating
appropriate heart failure treatment.42
Miscellaneous Mechanisms Implicated in the
Progression of HF in the Presence of CSA-CSR
CSA-CSR leads to cyclical oscillations in heart
rate and blood pressure through mechanisms similar to
those described for OSA: hypoxia, arousals from sleep,
and adrenergic activation.55 Similar adverse effect on
the cardiovascular system can be exerted by direct cyclic
activation of cardiovascular sympathetic neurons by
respiratory neurons in the brain stem.56,57 The presence
of cyclical oscillations in heart rate was shown to link
with a higher mortality rate in heart failure subjects.58,59

Treatment of Obstructive Sleep
Apnoea in Heart Failure
Weight loss is a cornerstone of therapy for obese
subjects, not only by reducing AHI, but also modifies
other traditional cardiovascular risk factors such as
hypertension, abnormal lipid metabolism, and insulin
resistance. For patients with a normal BMI, severe OSA
at diagnosis, or those having difficulty in losing weight,
specific treatment of OSA, such as nasal CPAP or an
oral appliance will be needed. On the other hand,
pharmacological agents is largely ineffective in reducing
the severity of OSA.59
Abolition of OSA by CPAP in patients with HF
prevents recurrent hypoxia, reduces nocturnal blood
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pressure and heart rate, 60 and increases arterial
baroreflex sensitivity. 61 In addition, two recent
randomized controlled studies had shown favourable
hemodynamic effect as well as significant improvement
in left ventricular systolic function in patients with heart
failure and OSA.62,63 The study by Kaneko et al which
involved 24 subjects on optimal anti-heart failure regime
with left ventricular ejection fraction (LVEF) of 45%
or less, treatment of coexisting obstructive sleep apnoea
by continuous positive airway pressure reduces systolic
blood pressure and improves left ventricular systolic
function (LVEF 25.0±2.8 increase to 33.8±2.4%
(P<0.001) after one month of treatment.62 Though the
results were encouraging, their follow-up period was
short and whether there is any carry over effect of the
CPAP after withdrawal of treatment was not performed.
In a similar study which had a longer period of followup (3 months), Mansfield et al. showed that treatment
of OSA among patients with HF leads not only to
improvement in cardiac function but changes in
sympathetic activity. The favourable cardiovascular
outcome after CPAP is probably achieved by a
combination of increase in heart rate variability,
reducing oxygen demand, increasing oxygen supply,
blunting of the sympathetic outflow and its vagal
modulation which64 is analogous to the chronic effects
of beta-blockade in HF.65 Although these short-term
results are encouraging, there remains a need for
randomized trials to determine whether the specific
treatment of OSA in HF will improve long-term
morbidity and mortality.

Treatment of Central Sleep
Apnoea in Heart Failure
Pharmacological Measures
The principal reason for treating CSA is the
potential to improve cardiovascular function, quality of
life, and longevity.51,52 Currently, there is no consensus
as to whether CSA should be treated, and if so, what
optimum therapy of CSA in HF might be. As discussed
previously, CSA-CSR is to some extent a manifestation
of advanced HF, the first consideration is to optimize
drug therapy. Aggressive diuresis to lower cardiac filling
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pressure along with angiotensin-converting enzyme
inhibitors and beta-blockers may reduce the severity of
CSA-CSR.66 Excessive diuresis , however, can lead to
metabolic alkalosis which may predispose to CSA-CSR
by narrowing the difference between ambient PaCO2
and the PaCO2 threshold for apnoea.67-69 Beta-blockers
may also reduce the adverse effects of excessive
sympathetic activation that is associated with CSR-CSA.
Should CSR-CSA persist despite aggressive medical
therapy for HF, other interventions may be considered
like nocturnal oxygen supplement and CPAP.

hypopnoea, nocturnal oxygenation, norepinephine level,
ejection fraction and distance walked over the control
group. However, there is no overall difference in quality
of life, number of hospitalization and survival and need
of transplantation.72 It is therefore likely that CSA is a
manifestation of poor heart function. While correction
of CSA may improve cardiac and general function, there
is no impact on the prognosis of HF itself.

Effect of Pacemaker and Device
Therapy on Heart Failure Patients
with OSA and CSA

Continuous Positive Airway Pressure (CPAP)
Via similar mechanism, HF patients with CSACSR and elevated LV end-diastolic pressure, CPAP
decreases LV afterload by increasing intrathoracic
pressure, augments stroke volume,43 and reduces cardiac
sympathetic activity. 44 It also decreases preload by
impeding venous return and reducing right and left
ventricular end-diastolic volume. 45 In patients with
CSA-CSR, short-term application of CPAP also reduces
the frequency of ventricular ectopic beats.46 which may
reduce the chance of occurrence of lethal arrhythmias.
A randomized trials of 3-months' duration have
demonstrated that nightly application of CPAP increases
LV ejection fraction, reduces mitral regurgitation and
nocturnal and daytime sympathetic nervous system
activity, and improves quality of life.48,70,71
There is also randomized data showing the
beneficial effect of CPAP on cardiovascular mortality
in HF subjects with CSR-CSA. Sin et al54 have shown
that of 29 patients with HF and CSA who received
CPAP, those who were complaint to CPAP experienced
a significant reduction in the combined rate of mortality
and cardiac transplantation over a 5-year period. A
larger, long-term, multicenter trial to test the effects of
CPAP on the combined rate of mortality and cardiac
transplantation in HF patients with CSA-CSR (the
CANadian Positive Airway Pressure trial for patients
with congestive heart failure and central sleep apnoea
[CANPAP]) is recently reported. Two hundred and fiftyeight patients with HF and ejection fraction of 24.5±
7.7% and significant AHI of 40±16/hour were
randomized for 2 years with CPAP or no CPAP. At
3 months, CPAP significantly improved apnoea and
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First reported in 2002, the study by Garrigue
et al has generated much discussion about the role of
pacemaker in the management of OSA and CSA in HF.
In his randomized trial, the effect of atrial overdrive
pacing on sleep apnoea in subjects without a history of
HF but had cardiac pacemakers implanted because of
symptomatic bradyarrhythmias was tested. Sleep studies
were performed, and among those found to have sleep
apnoea, the pacing rate was increased to 15 bpm above
the intrinsic heart rate. This overdrive pacing led to a
reduction in the frequency of both central and
obstructive apnoeas by approximately 50%. The study
period was short. Moreover, the mechanism responsible
for this effect was not determined. One possibility is
that some of these patients may have had pulmonary
congestion while in the recumbent position owing to
their bradyarrhythmias, or possibly diastolic
dysfunction. This may have stimulated hyperventilation
and predisposed to CSA. Overdrive pacing could have
augmented cardiac output and relieved pulmonary
congestion, thereby dampening respiratory controller
gain, reducing ventilation, increasing PaCO 2, and
reducing central apnoeas and hypopnoeas. This
mechanism would explain a reduction in central but not
obstructive events. If upper airway oedema accumulated
while the patient was in the recumbent position,39,74
augmentation of cardiac output by overdrive pacing
could have alleviated this oedema and increased
pharyngeal luminal dimensions.
The beneficial effects of overdrive pacing on sleep
apnoea have been re-tested in a recent study.75 In 16
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patients with severe OSA and normal ejection fraction,
atrial overdrive pacing at 15 bpm over the baseline heart
rate had no significant effect on OSA, both acutely and
when re-examined at one month, whereas CPAP had a
significant effect. It follows that pacing in patient with
SDB and normal LV function cannot improve OSA.
Cardiac resynchronization therapy using
biventricular pacing is now an established therapy for
HF.76,77 There is an improvement in ejection fraction,
exercise capacity, functional class and survival. By
improving HF, CSA was reported to be reduced.78 In
this study, 14/24 patients with significant CSA (AHI
>5/h) after cardiac resynchronization therapy had
reduced AHI from 19.2±10.3 to 4.6±4.4/h, P<0.001) and
improved Pittsburg sleep Quality Index. However, in
those without CSA, resynchronization therapy has no
impact on sleep apnoea and quality of sleep. Thus
resynchronization therapy has a distinct role in heart
failure patients in which CSA is a significant problem.

Conclusion
SDB is common in the general population and in
patients with HF. Treatment of OSA significantly
improves cardiovascular risk factors, although
improvement in clinical endpoints have yet to be proven.
In patients with HF, the role of treatment of CSA using
CPAP does not affect survival, but overall well being is
improved. Simple pacing therapy is probably not useful
for sleep apnoea. Cardiac resynchronization therapy has
a distinct role in improving SDB resulting from, or
associated, with HF.
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